Dingwall Steve, Lee Jung Bok, Guezguez Borhane, Fiebig Aline, McNicol Jamie, Boreham Douglas, Collins Tony J, Bhatia Mick
McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Canada.
Department of Biochemistry and Biomedical Sciences, Faculty of Health Sciences, McMaster University, Hamilton, Canada.
Oncotarget. 2015 Sep 8;6(26):22258-69. doi: 10.18632/oncotarget.4165.
Studies have implicated that a small sub-population of cells within a tumour, termed cancer stem cells (CSCs), have an enhanced capacity for tumour formation in multiple cancers and may be responsible for recurrence of the disease after treatment, including radiation. Although comparisons have been made between CSCs and bulk-tumour, the more important comparison with respect to therapy is between tumour-sustaining CSC versus normal stem cells that maintain the healthy tissue. However, the absence of normal known counterparts for many CSCs has made it difficult to compare the radiation responses of CSCs with the normal stem cells required for post-radiotherapy tissue regeneration and the maintenance of tissue homeostasis. Here we demonstrate that transformed human embryonic stem cells (t-hESCs), showing features of neoplastic progression produce tumours resistant to radiation relative to their normal counterpart upon injection into immune compromised mice. We reveal that t-hESCs have a reduced capacity for radiation induced cell death via apoptosis and exhibit altered cell cycle arrest relative to hESCs in vitro. t-hESCs have an increased expression of BclXL in comparison to their normal counterparts and re-sensitization of t-hESCs to radiation upon addition of BH3-only mimetic ABT737, suggesting that overexpression of BclXL underpins t-hESC radiation insensitivity. Using this novel discovery platform to investigate radiation resistance in human CSCs, our study indicates that chemotherapy targeting Bcl2-family members may prove to be an adjuvant to radiotherapy capable of targeting CSCs.
研究表明,肿瘤内一小部分细胞,即所谓的癌症干细胞(CSCs),在多种癌症中具有更强的肿瘤形成能力,可能是疾病治疗(包括放疗)后复发的原因。尽管已经对CSCs和实体瘤进行了比较,但就治疗而言,更重要的比较是维持肿瘤的CSC与维持健康组织的正常干细胞之间的比较。然而,许多CSCs缺乏已知的正常对应物,这使得难以将CSCs的辐射反应与放疗后组织再生和维持组织稳态所需的正常干细胞进行比较。在此,我们证明,具有肿瘤进展特征的转化人胚胎干细胞(t-hESCs)在注射到免疫缺陷小鼠体内后,相对于其正常对应物会产生抗辐射肿瘤。我们发现,t-hESCs通过凋亡产生辐射诱导细胞死亡的能力降低,并且在体外相对于hESCs表现出改变的细胞周期停滞。与正常对应物相比,t-hESCs中BclXL的表达增加,并且在添加仅含BH3的模拟物ABT737后t-hESCs对辐射重新敏感,这表明BclXL的过表达是t-hESCs辐射不敏感的基础。利用这个新的发现平台来研究人类CSCs的辐射抗性,我们的研究表明,靶向Bcl2家族成员的化疗可能被证明是一种能够靶向CSCs的放疗辅助手段。